연구동향 분석
박사

Pharmacogenomic landscape of patient-derived tumor cells informs precision medicine therapy in gliomas

신혜미 2019년

논문상세정보
인용/피인용
' Pharmacogenomic landscape of patient-derived tumor cells informs precision medicine therapy in gliomas' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Glioma
  • Patient derived cell
  • Precision medicine
  • drugscreening
  • pharmacogenomics
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
112 0

0.0%

' Pharmacogenomic landscape of patient-derived tumor cells informs precision medicine therapy in gliomas' 의 참고문헌

  • Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 67-73, doi:10.1177/108705719900400206 (1999).
  • Wu, T. D. & Nacu, S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 26, 873-881, doi:10.1093/bioinformatics/btq057 (2010).
  • Wolswijk, G. & Noble, M. Identification of an adult-specific glial progenitor cell. Development 105, 387-400 (1989).
  • Wilding, J. L. & Bodmer, W. F. Cancer cell lines for drug discovery and development. Cancer Res 74, 2377-2384, doi:10.1158/0008-5472.CAN-13-2971 (2014).
  • Weigelt, B. & Downward, J. Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. Front Oncol 2, 109, doi:10.3389/fonc.2012.00109 (2012).
  • Wang, L., Feng, Z., Wang, X., Wang, X. & Zhang, X. DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics 26, 136-138, doi:10.1093/bioinformatics/btp612 (2010).
  • Wang, A. et al. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget 7, 69760-69769, doi:10.18632/oncotarget.11951 (2016).
  • Touat, M., Idbaih, A., Sanson, M. & Ligon, K. L. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol 28, 1457-1472, doi:10.1093/annonc/mdx106 (2017).
  • Suzuki, H. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47, 458-468, doi:10.1038/ng.3273 (2015).
  • Soeda, A. et al. The evidence of glioblastoma heterogeneity. Sci Rep 5, 7979, doi:10.1038/srep07979 (2015).
  • Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783-792, doi:10.1056/NEJM200103153441101 (2001).
  • Shin, H. et al. Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas. Cancer Res Treat, doi:10.4143/crt.2019.036 (2019).
  • Seifert, M., Garbe, M., Friedrich, B., Mittelbronn, M. & Klink, B. Comparative transcriptomics reveals similarities and differences between astrocytoma grades. BMC Cancer 15, 952, doi:10.1186/s12885-015-1939-9 (2015).
  • Russo, A. et al. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget 6, 26814-26825, doi:10.18632/oncotarget.4254 (2015).
  • Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382-396, doi:10.1016/j.ccell.2015.02.007 (2015).
  • Ruas, M. & Peters, G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378, F115-177, doi:10.1016/s0304-419x(98)00017-1 (1998).
  • Roschke, A. V. et al. Karyotypic complexity of the NCI-60 drugscreening panel. Cancer Res 63, 8634-8647 (2003).
  • Rogers, T. W. et al. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas. J Neurooncol, doi:10.1007/s11060- 017-2710-7 (2017).
  • Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841-842, doi:10.1093/bioinformatics/btq033 (2010).
  • Parmar, S., Patel, K. & Pinilla-Ibarz, J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T 39, 483-519 (2014).
  • Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer 17, 57, doi:10.1186/s12943-018-0779-z (2018).
  • Paddock, M. N., Field, S. J. & Cantley, L. C. Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance. J Lipid Res 60, 747-752, doi:10.1194/jlr.S092130 (2019).
  • O'Brien, C. et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16, 3670-3683, doi:10.1158/1078-0432.CCR-09-2828 (2010).
  • McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069-2070, doi:10.1093/bioinformatics/btq330 (2010).
  • McCubrey, J. A. et al. Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Adv Biol Regul 57, 75-101, doi:10.1016/j.jbior.2014.09.016 (2015).
  • Martz, C. A. et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal 7, ra121, doi:10.1126/scisignal.aaa1877 (2014).
  • Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97-109, doi:10.1007/s00401-007-0243-4 (2007).
  • Lorz, A., Botesteanu, D. A. & Levy, D. Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment. Front Oncol 7, 189, doi:10.3389/fonc.2017.00189 (2017).
  • Liu, Q. et al. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol 94, 1-19, doi:10.1007/s11060-009-9919-z (2009).
  • Lee, J. K. et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet 49, 594-599, doi:10.1038/ng.3806 (2017).
  • Lee, J. K. et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat Genet 50, 1399-1411, doi:10.1038/s41588-018-0209-6 (2018).
  • Lan, Y. L. et al. The potential roles of dopamine in malignant glioma. Acta Neurol Belg 117, 613-621, doi:10.1007/s13760- 016-0730-2 (2017).
  • Komori, T., Sasaki, H. & Yoshida, K. [Revised WHO Classification of Tumours of the Central Nervous System:Summary of the Revision and Perspective]. No Shinkei Geka 44, 625-635, doi:10.11477/mf.1436203347 (2016).
  • Joo, K. M. et al. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep 3, 260-273, doi:10.1016/j.celrep.2012.12.013 (2013).
  • Jeuken, J. et al. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 19, 661-671, doi:10.1111/j.1750- 3639.2009.00320.x (2009).
  • Ivanescu, A. M., Oprea, M., Turbatu, A., Colita, A. & Lupu, A. R. Ibrutinib, a novel agent in relapsed or refractory chronic lymphocytic leukemia. Maedica (Buchar) 9, 217-218 (2014).
  • Hudis, C. A. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 357, 39-51, doi:10.1056/NEJMra043186 (2007).
  • Huang, S. & Pang, L. Comparing statistical methods for quantifying drug sensitivity based on in vitro dose-response assays. Assay Drug Dev Technol 10, 88-96, doi:10.1089/adt.2011.0388 (2012).
  • Horbinski, C., Hobbs, J., Cieply, K., Dacic, S. & Hamilton, R. L. EGFR expression stratifies oligodendroglioma behavior. Am J Pathol 179, 1638-1644, doi:10.1016/j.ajpath.2011.06.020 (2011).
  • Hamburg, M. A. & Collins, F. S. The path to personalized medicine. N Engl J Med 363, 301-304, doi:10.1056/NEJMp1006304 (2010).
  • Ghosh, D., Nandi, S. & Bhattacharjee, S. Combination therapy to checkmate Glioblastoma: clinical challenges and advances. Clin Transl Med 7, 33, doi:10.1186/s40169-018-0211-8 (2018).
  • Gelman, J. S. et al. Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS One 8, e53263, doi:10.1371/journal.pone.0053263 (2013).
  • Galli, R. et al. Isolation and characterization of tumorigenic, stemlike neural precursors from human glioblastoma. Cancer Res 64, 7011-7021, doi:10.1158/0008-5472.CAN-04-1364 (2004).
  • Gallego, O. Nonsurgical treatment of recurrent glioblastoma. Curr Oncol 22, e273-281, doi:10.3747/co.22.2436 (2015).
  • Fernandes, C. et al. in Glioblastoma (ed S. De Vleeschouwer) (2017).
  • Dunbar, E. & Yachnis, A. T. Glioma diagnosis: immunohistochemistry and beyond. Adv Anat Pathol 17, 187- 201, doi:10.1097/PAP.0b013e3181d98cd9 (2010).
  • Dienstmann, R., Rodon, J., Serra, V. & Tabernero, J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 13, 1021-1031, doi:10.1158/1535-7163.MCT-13-0639 (2014).
  • Das, S. & Marsden, P. A. Angiogenesis in glioblastoma. N Engl J Med 369, 1561-1563, doi:10.1056/NEJMcibr1309402 (2013).
  • Daniel, V. C. et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 69, 3364-3373, doi:10.1158/0008-5472.CAN-08-4210 (2009).
  • Claes, A., Idema, A. J. & Wesseling, P. Diffuse glioma growth: a guerilla war. Acta Neuropathol 114, 443-458, doi:10.1007/s00401-007-0293-7 (2007).
  • Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31, 213-219, doi:10.1038/nbt.2514 (2013).
  • Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370, 709-722, doi:10.1056/NEJMoa1308345 (2014).
  • Ceccarelli, M. et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164, 550- 563, doi:10.1016/j.cell.2015.12.028 (2016).
  • Cancer Genome Atlas Research, N. et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372, 2481-2498, doi:10.1056/NEJMoa1402121 (2015).
  • Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369, 32-42, doi:10.1056/NEJMoa1215637 (2013).
  • Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477, doi:10.1016/j.cell.2013.09.034 (2013).
  • Boots-Sprenger, S. H. et al. Significance of complete 1p/19q codeletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol 26, 922-929, doi:10.1038/modpathol.2012.166 (2013).
  • Bhattacharjee, S. & Nandi, S. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics. IUBMB Life 69, 929-937, doi:10.1002/iub.1696 (2017).
  • Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607, doi:10.1038/nature11003 (2012).
  • Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108, doi:10.1038/nature08460 (2009).
  • Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405- 409, doi:10.1038/nature11154 (2012).